Details of the Drug

General Information of Drug (ID: DMY4IWC)

Drug Name
LCB-2183
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 2 [1]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 206.2
Logarithm of the Partition Coefficient (xlogp) -0.5
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
Chemical Identifiers
Formula
C9H10N4O2
IUPAC Name
2-(ethoxymethyl)-3H-pteridin-4-one
Canonical SMILES
CCOCC1=NC2=NC=CN=C2C(=O)N1
InChI
InChI=1S/C9H10N4O2/c1-2-15-5-6-12-8-7(9(14)13-6)10-3-4-11-8/h3-4H,2,5H2,1H3,(H,11,12,13,14)
InChIKey
SFWVULIFVPNTOF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
135418284
CAS Number
133914-85-9
TTD ID
D01KNY

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine receptor (HR) TT7CXIM NOUNIPROTAC Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 LCB 2183 inhibits tracheal hyperreactivity and pulmonary inflammation in mouse airways. Eur J Pharmacol. 1995 Aug 25;282(1-3):103-9.
2 LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol. 1994 Aug;16(8):675-83.